# GEXVal

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/gexval

- Industry: Pharmaceuticals
- Headquarters: Fujisawa-shi, Japan
- Website: www.gexval.com
- Total disclosed funding: $14M
- Latest round: Series C (Jun 25, 2024)
- Investors on record: 13

## About

Based in Japan, GEXVal Inc. is a pharmaceutical company focused on developing innovative treatment options that enhance patient care, prioritizing affordability and accessibility for essential medications.GEXVal Inc., founded in 2018, is located in Fujisawa-shi, Japan. The company specializes in pharmaceuticals aimed at improving treatment access for patients. Juran Kato, the CEO, leads the firm which has secured a total of JPY 300 million in Series C funding from Alfresa Holdings as part of a larger JPY 860 million round. GEXVal has successfully completed 5 deals, with the most recent deal occurring on January 16, 2025. They have not undergone any significant strategic pivots.GEXVal specializes in the development and delivery of innovative pharmaceutical products aimed at enhancing treatment options for patients. The company's core offerings include a range of medicines designed to address various health conditions, focusing on affordability and accessibility to ensure that patients have timely access to essential treatments. GEXVal prioritizes patient needs and emphasizes research and development in its product pipeline, which reflects its commitment to delivering effective therapeutic solutions. The company serves a diverse clientele, including healthcare providers, hospitals, and organizations that facilitate patient care across various geographical markets, including Asia, Europe, and North America.GEXVal generates revenue through strategic partnerships and direct sales of its pharmaceutical products to healthcare providers and institutions. The company's transaction structure is primarily B2B, supplying products to hospitals and clinics that then provide them to end-users, such as patients in need of treatment. GEXVal’s revenue model includes one-time purchases of individual products or ongoing contracts with healthcare facilities to supply a range of medicines consistently. The firm's flagship products have garnered attention within the industry and are integral to its revenue stream, as they address significant treatment gaps while being priced competitively in the market. GEXVal's commitment to affordability and accessibility is reflected in its pricing strategies aimed at making essential medicines available to a broader patient population.In January 2025, GEXVal Inc. raised JPY 300 million in Series C funding, which is part of a larger JPY 860 million round. The company plans to utilize these funds for the research and development of Phase II clinical trials of their product "GXV-001". Additionally, GEXVal is strategizing for expansion into new geographical markets to enhance their reach and effectiveness by targeting regions across Asia, Europe, and North America. The introduction of new products in the pipeline is expected to further solidify their market presence.

## Funding rounds

- Series C, Jun 25, 2024, $0.7M — Mitsubishi UFJ Capital, SMBC Venture Capital, Mizuho Capital, UTC Investment, Oita Venture Capital, Axil Capital
- Series C, Dec 4, 2023, $3.1M — Mitsubishi UFJ Capital, SMBC Venture Capital, UTC Investment, Oita Venture Capital, Axil Capital
- Series B, Sep 10, 2021, $6.4M — Mitsubishi UFJ Capital, Yokohama Capital, TNP Group, LS Securities, Healthcare Innovation, Shiratori Pharmaceutical Co., Ltd., YK VENTURE PARTNERS Co., Ltd.
- Series A, Oct 5, 2018, $3.6M — Mitsubishi UFJ Capital, SMBC Venture Capital, Takeda Pharmaceutical, TNP Group

## Investors

- Mitsubishi UFJ Capital (https://capitalatlas.ai/funds/mitsubishi-ufj-capital) — Series A, Series B, Series C
- SMBC Venture Capital (https://capitalatlas.ai/funds/smbc-venture-capital) — Series A, Series C
- Takeda Pharmaceutical — Series A
- TNP Group (https://capitalatlas.ai/funds/tnp-group) — Series A, Series B
- Yokohama Capital (https://capitalatlas.ai/funds/yokohama-capital) — Series B
- LS Securities — Series B
- Healthcare Innovation — Series B
- Shiratori Pharmaceutical Co., Ltd. — Series B
- YK VENTURE PARTNERS Co., Ltd. — Series B
- UTC Investment (https://capitalatlas.ai/funds/utc-investment) — Series C
- Oita Venture Capital (https://capitalatlas.ai/funds/oita-venture-capital) — Series C
- Axil Capital (https://capitalatlas.ai/funds/axil-capital) — Series C
- Mizuho Capital (https://capitalatlas.ai/funds/mizuho-capital) — Series C